Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human study to investigate the skin tolerability of micro-projection array patches coated with inactivated split influenza virus haemagglutinin (HA) from A/Singapore/GP1908/2015 (A/Michigan/45/2015(H1N1)-like) vaccine in healthy volunteers

Next Previous
X
Search
Trial Profile

First-in-human study to investigate the skin tolerability of micro-projection array patches coated with inactivated split influenza virus haemagglutinin (HA) from A/Singapore/GP1908/2015 (A/Michigan/45/2015(H1N1)-like) vaccine in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs H1N1-like vaccine coated nanopatch (Primary) ; Influenza vaccine quadrivalent Seqirus
  • Indications Influenza virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Vaxxas

    • Most Recent Events

    • 17 Mar 2020 Results published in the Vaxxas Media Release
    • 17 Mar 2020 According to an Vaxxas media release, this study was published in the journal PLoS Medicine.
    • 24 Jul 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top